# A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

> **NCT06721143** · PHASE1,PHASE2 · RECRUITING · sponsor: **AION Healthspan, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Kidney Disease Stage 3

## Interventions

- **BIOLOGICAL:** AION-301
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06721143
- **Lead sponsor:** AION Healthspan, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-23
- **Primary completion:** 2027-01
- **Final completion:** 2027-05
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06721143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06721143, "A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06721143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*